Oculis (OCS) Leerink Global Healthcare Conference 2026 summary

Pipeline overview and strategic focus

• Three clinical-stage assets are in phase III, with a shift in focus to a neurodegeneration program now seen as the most promising for peak sales.

• The DME program (OCS-01) is the first and only topical product for retina, targeting both early intervention and patients unresponsive to anti-VEGF, representing a larger market than current treatments.

DME program: Clinical data and commercialization

• Phase II data showed a mean BCVA improvement of 7.8 letters, comparable to anti-VEGF injections, with efficacy in both naïve and previously treated patients.

• Two phase III studies (DIAMOND-1 and DIAMOND-2) will report in late Q2, with primary endpoint mean BCVA and secondary endpoint responders; positive results will lead to immediate filing.

• Commercial launch plans call for a field force of 50-60 FTEs, leveraging the product’s differentiation and existing market awareness.

• Pricing strategy targets $10,000 per year, positioned above Ozurdex ($8,000) but below anti-VEGF ($8,000-$16,000), aiming for rapid penetration and combination use.

Dry eye program: Precision medicine approach

• Biomarker-driven strategy identifies TNFR1-positive patients, enabling a focused phase III trial with higher probability of success and improved compliance.

• The phase III PREDICT-1 trial began last year, with first patient visits imminent and readout expected in Q4; subsequent studies will be run in parallel.

• Pricing is expected at parity with MIEBO ($11,000/year), with higher compliance projected to drive greater patient value.